What is the recommended treatment for acute pulmonary and disseminated histoplasmosis?

Treatment of Histoplasmosis

For acute pulmonary histoplasmosis with moderate-to-severe symptoms and disseminated histoplasmosis, start with liposomal amphotericin B (3 mg/kg daily) for 1-2 weeks, followed by itraconazole (200 mg twice daily) for at least 12 months. 1, 2

Acute Pulmonary Histoplasmosis

Moderately Severe to Severe Disease

• Initiate liposomal amphotericin B (L-AmB) 3-5 mg/kg IV daily for 1-2 weeks 1, 2
• Alternative lipid formulations at 5 mg/kg daily are acceptable if L-AmB is unavailable or cost-prohibitive 2
• Amphotericin B deoxycholate (0.7-1.0 mg/kg daily) can be used in patients at low risk for nephrotoxicity 2
• Transition to itraconazole 200 mg twice daily for a total treatment duration of 12 weeks 2
• Add methylprednisolone (0.5-1.0 mg/kg IV daily) during the first 1-2 weeks if respiratory complications develop, including hypoxemia or significant respiratory distress 2

The evidence strongly supports L-AmB over conventional amphotericin B deoxycholate—a randomized trial demonstrated superior response rates (88% vs 64%) and lower mortality (2% vs 13%) with liposomal formulation 2.

Mild-to-Moderate Disease

• Treatment is usually unnecessary 2
• Consider itraconazole 200 mg once or twice daily for 6-12 weeks only if symptoms persist beyond 1 month 2
• Most cases resolve spontaneously within 3 weeks without intervention 2

Progressive Disseminated Histoplasmosis

Moderately Severe to Severe Disease

• Start with liposomal amphotericin B 3 mg/kg IV daily for 1-2 weeks 2
• Follow with itraconazole 200 mg twice daily for at least 12 months 2
• In immunocompromised patients (especially those with HIV), L-AmB at 3-5 mg/kg daily for 10-14 days is strongly recommended 1
• Maintenance itraconazole (200 mg twice daily) should continue for 12 months pending immune reconstitution 1

Critical point: Continue L-AmB despite nephrotoxicity in severe cases—the mortality benefit outweighs renal risks, and renal function often improves despite continued therapy 2.

Mild-to-Moderate Disease

• Itraconazole 200 mg twice daily for at least 12 months 2
• Load with 200 mg three times daily for 3 days, then twice daily 2

Immunosuppressed Patients

• Lifelong suppressive therapy with itraconazole 200 mg daily may be required if immunosuppression cannot be reversed 2
• In HIV patients, suppressive therapy can be discontinued once CD4 count exceeds 150 cells/mm³ with sustained viral suppression 2

Monitoring and Key Considerations

Itraconazole Management

• Measure itraconazole blood levels after 2 weeks of therapy to ensure adequate drug exposure 2
• Use the oral solution on an empty stomach for better absorption than capsules 2
• Capsules require high gastric acidity—take with food or acidic beverages 2
• Avoid capsules in patients on proton pump inhibitors, H2 blockers, or antacids 2
• Monitor hepatic enzymes at baseline, weeks 1,2, and 4, then every 3 months 2

Disease Monitoring

• Measure Histoplasma antigen levels during therapy and for 12 months after completion to monitor for relapse 2
• Persistent low-level antigenuria alone does not mandate prolonged treatment if the patient has completed appropriate therapy and shows no clinical evidence of active infection 2

Common Pitfalls to Avoid

1. Do not use fluconazole as first-line therapy—it has lower efficacy than itraconazole (70% vs near 100%) and resistance can develop 2
2. Do not withhold antiretroviral therapy in HIV patients due to concerns about immune reconstitution inflammatory syndrome—the syndrome is rare and usually mild, while outcomes are significantly better with concurrent antiretroviral therapy 2
3. Do not switch from L-AmB to azoles prematurely in severe disease due to nephrotoxicity concerns—the mortality benefit justifies continued use 2
4. Voriconazole is not routinely recommended for histoplasmosis 1